

**FISCAL NOTE**  
**Requested by Legislative Council**  
**03/17/2021**

Amendment to: Engrossed HB 1288

- 1 A. **State fiscal effect:** *Identify the state fiscal effect and the fiscal effect on agency appropriations compared to funding levels and appropriations anticipated under current law.*

	2019-2021 Biennium		2021-2023 Biennium		2023-2025 Biennium	
	General Fund	Other Funds	General Fund	Other Funds	General Fund	Other Funds
<b>Revenues</b>						
<b>Expenditures</b>			\$479,585	\$1,297,885	\$575,696	\$1,557,686
<b>Appropriations</b>			\$479,585	\$1,297,885	\$575,696	\$1,557,686

- 1 B. **County, city, school district and township fiscal effect:** *Identify the fiscal effect on the appropriate political subdivision.*

	2019-2021 Biennium	2021-2023 Biennium	2023-2025 Biennium
<b>Counties</b>			
<b>Cities</b>			
<b>School Districts</b>			
<b>Townships</b>			

- 2 A. **Bill and fiscal impact summary:** *Provide a brief summary of the measure, including description of the provisions having fiscal impact (limited to 300 characters).*

HB1288 would require the Department's Medicaid program, including Medicaid Expansion, to cover costs of a continuous glucose monitoring (CGM) device for an individual with diabetes. Costs are estimated at \$1,777,470 for 2021-2023 biennium, of which \$479,585 is General Fund.

- B. **Fiscal impact sections:** *Identify and provide a brief description of the sections of the measure which have fiscal impact. Include any assumptions and comments relevant to the analysis.*

Section 1 of HB1288 would require that the Department provide coverage for CGM devices under the Department's Medicaid program including Medicaid Expansion. Expenditures are estimated to be \$1,777,470, of which \$479,585 is General Fund, for the 2021-2023 biennium.

The Department currently has 1,683 recipients receiving blood glucose test strips and for the purpose of this fiscal note, it was assumed only 40% of recipients would switch to CGM's during the first year and 60% of all recipients for the second year. Estimated costs for a CGM were estimated to be \$1,056.13 per year.

3. **State fiscal effect detail:** *For information shown under state fiscal effect in 1A, please:*

- A. **Revenues:** *Explain the revenue amounts. Provide detail, when appropriate, for each revenue type and fund affected and any amounts included in the executive budget.*

- B. **Expenditures:** *Explain the expenditure amounts. Provide detail, when appropriate, for each agency, line item, and fund affected and the number of FTE positions affected.*

Section 1 of HB1288 would require that the Department provide coverage for CGM devices under the Department's Medicaid program including Medicaid Expansion. Expenditures are estimated to be \$1,777,470, of which \$479,585 is General Fund, for the 2021-2023 biennium.

The Department currently has 1,683 recipients receiving blood glucose test strips and for the purpose of this fiscal note, it was assumed only 40% of recipients would switch to CGM's during the first year and 60% of all recipients for the second year. Estimated costs for a CGM were estimated to be \$1,056.13 per year.

- C. **Appropriations:** *Explain the appropriation amounts. Provide detail, when appropriate, for each agency and fund affected. Explain the relationship between the amounts shown for expenditures and appropriations. Indicate whether the appropriation or a part of the appropriation is included in the executive budget or relates to a continuing appropriation.*

For the 2021-2023 biennium, the Department of Human Services would need an appropriation increase in the Medical Grants line of \$1,777,470, of which \$479,585 would be General Fund, to HB1012.

For the 2023-2025 biennium, the Department of Human Services would need an appropriation in the Medical Grants line of \$2,133,382, of which \$575,696 would be General Fund.

**Name:** Rhonda Obrigewitch

**Agency:** Human Services

**Telephone:** 7013284585

**Date Prepared:** 03/17/2021